Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1680721rdf:typepubmed:Citationlld:pubmed
pubmed-article:1680721lifeskim:mentionsumls-concept:C0058698lld:lifeskim
pubmed-article:1680721lifeskim:mentionsumls-concept:C0001655lld:lifeskim
pubmed-article:1680721lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:1680721lifeskim:mentionsumls-concept:C0282151lld:lifeskim
pubmed-article:1680721lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:1680721lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:1680721lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:1680721pubmed:issue1lld:pubmed
pubmed-article:1680721pubmed:dateCreated1991-11-1lld:pubmed
pubmed-article:1680721pubmed:abstractTextACTH-(1-24) decreased the binding of the dopamine D2 receptor agonist, [3H]N-propylnorapomorphine ([3H]NPA), to rat striatal membranes in a concentration-dependent manner, with a Ki of 5 x 10(-7) M. Saturation curves for [3H]NPA binding in the presence of increasing concentrations of ACTH-(1-24) were performed. Scatchard analysis in the presence of ACTH-(1-24) revealed an increased dissociation constant (Kd), while the binding capacity (Bmax) was not affected by the peptide, suggesting an apparent competitive interaction between ACTH-(1-24) and [3H]NPA. ACTH-(1-24) also reduced the binding of the dopamine D2 receptor antagonist [3H]spiperone to striatal membranes, with a Ki of 10(-6) M. Much higher concentrations of ACTH-(1-24), up to 10(-4) M, were needed for the displacement of appropriate radiolabelled ligands from dopamine D1 receptors, serotonin 5-HT1A, serotonin 5-HT1B, muscarinic M1 acetylcholine and histamine H1 receptors. ACTH-(1-24) also inhibited the binding of [3H]spiperone to dopamine D2 receptors in membranes of the pituitary gland, the septum and the substantia nigra. ACTH-(1-39) and most ACTH fragments and analogs were less potent than ACTH-(1-24) in displacing [3H]NPA from the dopamine D2 receptor in striatal membranes. In general there was a relationship between displacing potency and chain length. ACTH-(7-16)-NH2 and benzyloxycarbonyl-ACTH-(8-16)-NH2, however, were more potent than ACTH-(1-24) in reducing the binding of [3H]NPA to dopamine D2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1680721pubmed:languageenglld:pubmed
pubmed-article:1680721pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:citationSubsetIMlld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1680721pubmed:statusMEDLINElld:pubmed
pubmed-article:1680721pubmed:monthMaylld:pubmed
pubmed-article:1680721pubmed:issn0014-2999lld:pubmed
pubmed-article:1680721pubmed:authorpubmed-author:VersteegD HDHlld:pubmed
pubmed-article:1680721pubmed:authorpubmed-author:Van NispenJ...lld:pubmed
pubmed-article:1680721pubmed:authorpubmed-author:De BoerTTlld:pubmed
pubmed-article:1680721pubmed:authorpubmed-author:TonnaerJ AJAlld:pubmed
pubmed-article:1680721pubmed:authorpubmed-author:FlorijnW JWJlld:pubmed
pubmed-article:1680721pubmed:issnTypePrintlld:pubmed
pubmed-article:1680721pubmed:day25lld:pubmed
pubmed-article:1680721pubmed:volume207lld:pubmed
pubmed-article:1680721pubmed:ownerNLMlld:pubmed
pubmed-article:1680721pubmed:authorsCompleteYlld:pubmed
pubmed-article:1680721pubmed:pagination43-50lld:pubmed
pubmed-article:1680721pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:meshHeadingpubmed-meshheading:1680721-...lld:pubmed
pubmed-article:1680721pubmed:year1991lld:pubmed
pubmed-article:1680721pubmed:articleTitleACTH/MSH-like peptides inhibit the binding of dopaminergic ligands to the dopamine D2 receptor in vitro.lld:pubmed
pubmed-article:1680721pubmed:affiliationRudolf Magnus Institute, Department of Pharmacology, Medical Faculty, University of Utrecht, The Netherlands.lld:pubmed
pubmed-article:1680721pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1680721pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:1680721pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1680721lld:pubmed